219 related articles for article (PubMed ID: 20360534)
21. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
22. Persistent HPV infection and cervical cancer risk: is the scientific rationale for changing the screening paradigm enough?
Franco EL
J Natl Cancer Inst; 2010 Oct; 102(19):1451-3. PubMed ID: 20841606
[No Abstract] [Full Text] [Related]
23. [Impact of HPV testing on cervical cancer screening].
Li G
Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):241-5. PubMed ID: 26080933
[No Abstract] [Full Text] [Related]
24. HPV primary screening for cervical cancer: more pain than protection.
Davey DD; Armenti CA
Diagn Cytopathol; 2000 Jun; 22(6):333-5. PubMed ID: 10820524
[No Abstract] [Full Text] [Related]
25. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3.
Kotaniemi-Talonen L; Anttila A; Malila N; Tarkkanen J; Laurila P; Hakama M; Nieminen P
Eur J Cancer; 2008 Mar; 44(4):565-71. PubMed ID: 18248809
[TBL] [Abstract][Full Text] [Related]
26. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial.
Broberg G; Jonasson JM; Ellis J; Gyrd-Hansen D; Anjemark B; Glantz A; Söderberg L; Ryd ML; Holtenman M; Milsom I; Strander B
Int J Cancer; 2013 Jul; 133(1):164-71. PubMed ID: 23233356
[TBL] [Abstract][Full Text] [Related]
27. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
28. [Papillomavirus screening: shall it be performed systematically?].
Agius G; Beby-Defaux A
Transfus Clin Biol; 2003 Apr; 10(2):86-9. PubMed ID: 12763151
[No Abstract] [Full Text] [Related]
29. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
30. Primary HPV screening for cervical cancer.
Bhatla N; Singhal S
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():98-108. PubMed ID: 32291178
[TBL] [Abstract][Full Text] [Related]
31. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
32. Comparing cytology, colposcopy and human papillomavirus cervical intraepithelial lesion screening methods in women with systemic lupus erythematosus.
García-Carrasco M; Mendoza-Pinto C; Méndez-Martínez S; Rodríguez-Reyes A; Munguía-Realpozo P; Taboada-Cole A; Vallejo-Ruiz V; Etchegaray-Morales I; Jiménez-Herrera R; Juárez-Melchor D; Villanueva-López I
Lupus; 2020 Aug; 29(9):1060-1066. PubMed ID: 32501171
[TBL] [Abstract][Full Text] [Related]
33. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.
Coste J; Cochand-Priollet B; de Cremoux P; Le Galès C; Cartier I; Molinié V; Labbé S; Vacher-Lavenu MC; Vielh P;
BMJ; 2003 Apr; 326(7392):733. PubMed ID: 12676841
[TBL] [Abstract][Full Text] [Related]
34. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
35. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
36. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.
Rodríguez AC; Schiffman M; Herrero R; Wacholder S; Hildesheim A; Castle PE; Solomon D; Burk R;
J Natl Cancer Inst; 2008 Apr; 100(7):513-7. PubMed ID: 18364507
[TBL] [Abstract][Full Text] [Related]
37. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.
Clavel C; Masure M; Bory JP; Putaud I; Mangeonjean C; Lorenzato M; Nazeyrollas P; Gabriel R; Quereux C; Birembaut P
Br J Cancer; 2001 Jun; 84(12):1616-23. PubMed ID: 11401314
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
